| GA21716-1g |
|
2022956-36-9 |
Fmoc-Lys(4-methoxytrityl)-OPfp
|
0 |
C47H39F5N2O5 |
|
|
|
| GA21715-5g |
|
159857-60-0 |
Fmoc-Lys(4-methoxytrityl)-OH
|
0 |
C41H40N2O5 |
|
|
|
| GA21715-1g |
|
159857-60-0 |
Fmoc-Lys(4-methoxytrityl)-OH
|
0 |
C41H40N2O5 |
|
|
|
| GA21714-5g |
|
176380-53-3 |
|
0 |
C19H21NO4 |
|
|
|
| GA21714-1g |
|
176380-53-3 |
|
0 |
C19H21NO4 |
|
|
|
| GA21713-25g |
|
133054-21-4 |
Fmoc-L-thiazolidine-4-carboxylic acid
|
0 |
C19H17NO4S |
|
|
|
| GA21713-5g |
|
133054-21-4 |
Fmoc-L-thiazolidine-4-carboxylic acid
|
0 |
C19H17NO4S |
|
|
|
| GA21712-25g |
|
955048-89-2 |
Fmoc-Leu-Thr(Psi(Me,Me)pro)-OH
|
0 |
C28H34N2O6 |
|
|
|
| GA21712-5g |
|
955048-89-2 |
Fmoc-Leu-Thr(Psi(Me,Me)pro)-OH
|
0 |
C28H34N2O6 |
|
|
|
| GA21711-25g |
|
339531-50-9 |
Fmoc-Leu-Ser(Psi(Me,Me)pro)-OH
|
0 |
C27H32N2O6 |
|
|
|
| GA21711-5g |
|
339531-50-9 |
Fmoc-Leu-Ser(Psi(Me,Me)pro)-OH
|
0 |
C27H32N2O6 |
|
|
|
| GA21710-5g |
|
— |
Fmoc-Leu-SASRIN™ resin (200-400 mesh, 0.5-0.8 mmol/g)
|
0 |
— |
|
|
|
| GA21710-1g |
|
— |
Fmoc-Leu-SASRIN™ resin (200-400 mesh, 0.5-0.8 mmol/g)
|
0 |
— |
|
|
|
| GA21709-5g |
|
130832-25-6 |
|
0 |
C26H30N2O5 |
|
|
|
| GA21709-1g |
|
130832-25-6 |
|
0 |
C26H30N2O5 |
|
|
|
| GA21708-5g |
|
82007-05-4 |
|
0 |
C23H26N2O5 |
|
|
|
| GA21708-1g |
|
82007-05-4 |
|
0 |
C23H26N2O5 |
|
|
|
| GA21707-1g |
|
1926163-06-5 |
Fmoc-Leu-Cys(Psi(Dmp,H)pro)-OH
|
0 |
C33H36N2O7S |
|
|
|
| GA21706-5g |
|
320384-09-6 |
Fmoc-L-cysteic acid . disodium salt
|
0 |
C18H15NNa2O7S |
|
|
|
| GA21706-1g |
|
320384-09-6 |
Fmoc-L-cysteic acid . disodium salt
|
0 |
C18H15NNa2O7S |
|
|
|
